NEI Research News

Imagine you are building a house. You would need a team of specialists, including an architect, a general contractor, carpenters, an electrician, a plumber and many others.

Three studies reported in Nature Genetics have converged on the same gene as a rare, but powerful risk factor for age-related macular degeneration (AMD), a common cause of vision loss in older people.

Adding omega-3 fatty acids did not improve a combination of nutritional supplements commonly recommended for treating age-related macular degeneration (AMD), a major cause of vision loss among older Americans.

Targeting cholesterol metabolism in the eye might help prevent a severe form of age-related macular degeneration (AMD), one of the most common causes of blindness in older Americans.

An international group of researchers has discovered seven new regions of the human genome—called loci-that are associated with increased risk of age-related macular degeneration (AMD), a leading cause of blindness.

Changes in how genes in the immune system function may result in age-related macular degeneration (AMD), the leading cause of visual impairment in older adults, based on preliminary research conducted by National Institutes of Health (NIH) investigators.

Researchers have developed a new prosthetic technique that can restore vision to blind mice. The approach could potentially be further developed to improve sight in blind people.

At two years, Avastin (bevacizumab) and Lucentis (ranibizumab injection), two widely used drugs to treat age-related macular degeneration (AMD).

Researchers are reporting results from the first year of a two-year clinical trial that Avastin, a drug approved to treat some cancers and that is commonly used off-label to treat age-related macular degeneration (AMD).

More than 72,000 clinical photographs illustrate age-related eye disease progression